Watch RXRX. Know when insiders buy.
One email the day a filing lands. Free.
Work order
50
WATCH · insiders 45, shorts 54
Insiders, 90 days
−$100K
net selling · 0 buys, 1 sell
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $1.8BP/E —DIV YIELD —FCF YIELD -19.13%REV TTM $54.9M −15.1%NET INCOME −$518.9MNET CASH $545M52W 2.84 – 6.79SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | $7.7M | −60.1% | -49.8% | −$135M | −$131M | — | -0.25 | −$105.9M | $44K | −$106M | Aug 5 |
| Q1 2026 · Mar 31 | $6.5M | −56.1% | -93.0% | −$128.5M | −$117.5M | — | -0.22 | −$81.1M | $258K | −$81.4M | May 6 |
| Q4 2025 · Dec 31derived | $35.5M | +681.7% | 59.8% | −$108.3M | −$108.1M | — | -0.17 | −$46.1M | $1.2M | −$47.3M | Feb 25 |
| Q3 2025 · Sep 30 | $5.2M | −80.2% | -183.8% | −$172.2M | −$162.3M | — | -0.36 | −$117.4M | $243K | −$117.6M | Nov 5 |
| Q2 2025 · Jun 30 | $19.2M | +33.3% | -4.9% | −$176.2M | −$171.9M | — | -0.41 | −$76.4M | $3.1M | −$79.6M | Aug 5 |
| Q1 2025 · Mar 31 | $14.7M | +6.9% | -48.0% | −$191.4M | −$202.5M | — | -0.50 | −$132M | $1.8M | −$133.8M | May 6 |
| Q4 2024 · Dec 31derived | $4.5M | −58.3% | -181.4% | −$183.8M | −$178.9M | — | -0.57 | −$115.4M | $1.3M | −$116.7M | Feb 25 |
| Q3 2024 · Sep 30 | $26.1M | +147.6% | 53.7% | −$98.4M | −$95.8M | — | -0.34 | −$59.2M | $4.6M | −$63.8M | Nov 5 |
| Q2 2024 · Jun 30 | $14.4M | — | 36.2% | −$100.5M | −$97.5M | — | -0.40 | −$82.2M | $1.2M | −$83.4M | Aug 5 |
| Q1 2024 · Mar 31 | $13.8M | — | 19.1% | −$96.3M | −$91.4M | — | -0.39 | −$102.3M | $6.7M | −$109M | May 5 |
| Q4 2023 · Dec 31derived | $10.9M | — | 9.3% | −$98.9M | −$93M | — | -0.42 | −$74.1M | $2.1M | −$76.1M | Feb 25 |
| Q3 2023 · Sep 30 | $10.5M | — | -3.3% | −$99.5M | −$93M | — | -0.43 | −$72.9M | $745K | −$73.7M | Nov 6 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | $74.7M | 5.0% | −$648.1M | −$644.8M | -863.4% | -1.44 | −$371.8M | $6.5M | −$378.3M | — | — |
| FY2024 · to Dec 31 | $58.8M | 23.1% | −$479M | −$463.7M | -788.0% | -1.69 | −$359.2M | $13.7M | −$372.9M | — | — |
| FY2023 · to Dec 31 | $44.6M | 4.5% | −$350.1M | −$328.1M | -736.0% | -1.58 | −$287.8M | $12M | −$299.7M | — | — |
| FY2022 · to Dec 31 | $39.8M | -21.2% | −$245.7M | −$239.5M | -601.0% | -1.36 | −$83.5M | $37.1M | −$120.6M | — | — |
| FY2021 · to Dec 31 | $10.2M | 100.0% | −$182.8M | −$186.5M | -1832.2% | -1.49 | −$158.6M | $39.8M | −$198.4M | — | — |
| FY2020 · to Dec 31 | $4M | 100.0% | −$84.6M | −$87M | -2196.0% | -3.99 | −$45.4M | $5.8M | −$51.2M | — | — |
Every number comes from RECURSION PHARMACEUTICALS, INC.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.